{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:12:43Z","timestamp":1758931963366,"version":"3.44.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,26]]},"DOI":"10.7759\/cureus.93303","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T18:24:39Z","timestamp":1758911079000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Sodium-Glucose Co-transporter 2 Inhibitors and Thiazolidinediones in Reducing Adverse Cardiovascular Events in Type 2 Diabetes"],"prefix":"10.7759","author":[{"given":"Arshad","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzair","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talha","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faryal","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Moeed","family":"Baig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Ambreen","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma CX","year":"2022","unstructured":"Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022, 21:74. 10.1186\/s12933-022-01516-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3329\/medtoday.v34i1.58671","article-title":"Stroke and coronary heart diseases, global and Asian trend and risk factors-a perspective","volume":"34","author":"Rashid SMA","year":"2022","unstructured":"Rashid SMA, Hossain SM. Stroke and coronary heart diseases, global and Asian trend and risk factors-a perspective. Medicine Today. 2022, 34:27-35. 10.3329\/medtoday.v34i1.58671","journal-title":"Medicine Today"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01877-6","article-title":"Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study","volume":"22","author":"Sohn M","year":"2023","unstructured":"Sohn M, Dietrich JW, Nauck MA, Lim S. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study. Cardiovasc Diabetol. 2023, 22:153. 10.1186\/s12933-023-01877-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14796678.2025.2464449","article-title":"The effect of sodium-glucose co-transporter 2 inhibitors on clinical outcomes after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Khan U","year":"2025","unstructured":"Khan U, Amin AM, Mohamed Taha A, et al.. The effect of sodium-glucose co-transporter 2 inhibitors on clinical outcomes after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Future Cardiol. 2025, 21:177-90. 10.1080\/14796678.2025.2464449","journal-title":"Future Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94945-4","article-title":"Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Tsai WH","year":"2021","unstructured":"Tsai WH, Chuang SM, Liu SC, et al.. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep. 2021, 11:15364. 10.1038\/s41598-021-94945-4","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-025-00612-4","article-title":"The many facets of PPAR-\u03b3 agonism in obesity and associated comorbidities: benefits, risks, challenges, and future directions","volume":"14","author":"Kounatidis D","year":"2025","unstructured":"Kounatidis D, Vallianou NG, Rebelos E, et al.. The many facets of PPAR-\u03b3 agonism in obesity and associated comorbidities: benefits, risks, challenges, and future directions. Curr Obes Rep. 2025, 14:19. 10.1007\/s13679-025-00612-4","journal-title":"Curr Obes Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14687","article-title":"Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance","volume":"24","author":"Spence JD","year":"2022","unstructured":"Spence JD, Viscoli C, Kernan WN, et al.. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes Obes Metab. 2022, 24:1150-8. 10.1111\/dom.14687","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000239694.19359.88","article-title":"Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study","volume":"37","author":"Ohira T","year":"2006","unstructured":"Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke. 2006, 37:2493-8. 10.1161\/01.STR.0000239694.19359.88","journal-title":"Stroke"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13350","article-title":"Review of cadmium exposure and smoking-independent effects on atherosclerotic cardiovascular disease in the general population","volume":"290","author":"Fagerberg B","year":"2021","unstructured":"Fagerberg B, Barregard L. Review of cadmium exposure and smoking-independent effects on atherosclerotic cardiovascular disease in the general population. J Intern Med. 2021, 290:1153-79. 10.1111\/joim.13350","journal-title":"J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.09.050","article-title":"An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials","volume":"324","author":"Yu J","year":"2021","unstructured":"Yu J, Zhou Z, Mahaffey KW, et al.. An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. Int J Cardiol. 2021, 324:165-72. 10.1016\/j.ijcard.2020.09.050","journal-title":"Int J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212384","article-title":"The effects of SGLT2 inhibitors on blood pressure and other cardiometabolic risk factors","volume":"25","author":"Katsimardou A","year":"2024","unstructured":"Katsimardou A, Theofilis P, Vordoni A, Doumas M, Kalaitzidis RG. The effects of SGLT2 inhibitors on blood pressure and other cardiometabolic risk factors. Int J Mol Sci. 2024, 25:12384. 10.3390\/ijms252212384","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/0115733998254798231005095627","article-title":"Thiazolidinedione as a promising medicinal scaffold for the treatment of type 2 diabetes","volume":"20","author":"Singh G","year":"2024","unstructured":"Singh G, Kumar R, Desna DS, Chaudhary M, Kaur C, Khurrana N. Thiazolidinedione as a promising medicinal scaffold for the treatment of type 2 diabetes. Curr Diabetes Rev. 2024, 20:e201023222411. 10.2174\/0115733998254798231005095627","journal-title":"Curr Diabetes Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.768850","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors in patients with concurrent type 2 diabetes mellitus and non-alcoholic steatohepatitis: a review of the evidence","volume":"12","author":"Yabiku K","year":"2021","unstructured":"Yabiku K. Efficacy of sodium-glucose cotransporter 2 inhibitors in patients with concurrent type 2 diabetes mellitus and non-alcoholic steatohepatitis: a review of the evidence. Front Endocrinol (Lausanne). 2021, 12:768850. 10.3389\/fendo.2021.768850","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1089\/met.2022.0004","article-title":"Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome","volume":"20","author":"Premji R","year":"2022","unstructured":"Premji R, Nylen ES, Naser N, Gandhi S, Burman KD, Sen S. Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome. Metab Syndr Relat Disord. 2022, 20:321-8. 10.1089\/met.2022.0004","journal-title":"Metab Syndr Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann LE","year":"2024","unstructured":"Bechmann LE, Emanuelsson F, Nordestgaard BG, Benn M. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis. 2024, 394:117236. 10.1016\/j.atherosclerosis.2023.117236","journal-title":"Atherosclerosis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2022.2014322","article-title":"Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease","volume":"17","author":"Scheen AJ","year":"2022","unstructured":"Scheen AJ, Delanaye P. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Rev Endocrinol Metab. 2022, 17:35-46. 10.1080\/17446651.2022.2014322","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.05.005","article-title":"Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial","volume":"79","author":"Heerspink HJ","year":"2022","unstructured":"Heerspink HJ, Oshima M, Zhang H, et al.. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. Am J Kidney Dis. 2022, 79:244-56.e1. 10.1053\/j.ajkd.2021.05.005","journal-title":"Am J Kidney Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha KM","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023, 5:82-90. 10.36628\/ijhf.2022.0030","journal-title":"Int J Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.01.006","article-title":"Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Singh AK","year":"2021","unstructured":"Singh AK, Singh R. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2021, 15:351-9. 10.1016\/j.dsx.2021.01.006","journal-title":"Diabetes Metab Syndr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02328-6","article-title":"Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial","volume":"23","author":"Fitchett D","year":"2024","unstructured":"Fitchett D, Zinman B, Inzucchi SE, et al.. Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2024, 23:248. 10.1186\/s12933-024-02328-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0160","article-title":"Comparative effects of sodium-glucose cotransporter 2 inhibitor and thiazolidinedione treatment on risk of stroke among patients with type 2 diabetes mellitus","volume":"46","author":"Lee SE","year":"2022","unstructured":"Lee SE, Nam H, Choi HS, Kim H, Kyoung DS, Kim KA. Comparative effects of sodium-glucose cotransporter 2 inhibitor and thiazolidinedione treatment on risk of stroke among patients with type 2 diabetes mellitus. Diabetes Metab J. 2022, 46:567-77. 10.4093\/dmj.2021.0160","journal-title":"Diabetes Metab J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2022.2105693","article-title":"Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties","volume":"18","author":"Scheen AJ","year":"2022","unstructured":"Scheen AJ. Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opin Drug Metab Toxicol. 2022, 18:381-93. 10.1080\/17425255.2022.2105693","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01294-7","article-title":"Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug","volume":"20","author":"Nesti L","year":"2021","unstructured":"Nesti L, Tric\u00f2 D, Mengozzi A, Natali A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021, 20:109. 10.1186\/s12933-021-01294-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","article-title":"Pioglitazone and barriers to effective post-stroke comorbidity management in stroke survivors with diabetes","volume":"29","author":"Azhari H","year":"2024","unstructured":"Azhari H, Hewitt J, Smith A, O'Neill M, Quinn T, Dawson J. Pioglitazone and barriers to effective post-stroke comorbidity management in stroke survivors with diabetes. Neurosciences (Riyadh). 2024, 29:44-50.","journal-title":"Neurosciences (Riyadh)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15427","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild\/moderate chronic kidney disease","volume":"26","author":"Rhee JJ","year":"2024","unstructured":"Rhee JJ, Han J, Montez-Rath ME, Chertow GM. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild\/moderate chronic kidney disease. Diabetes Obes Metab. 2024, 26:1273-81. 10.1111\/dom.15427","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/409068-comparative-effectiveness-of-sodium-glucose-co-transporter-2-inhibitors-and-thiazolidinediones-in-reducing-adverse-cardiovascular-events-in-type-2-diabetes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T18:24:40Z","timestamp":1758911080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/409068-comparative-effectiveness-of-sodium-glucose-co-transporter-2-inhibitors-and-thiazolidinediones-in-reducing-adverse-cardiovascular-events-in-type-2-diabetes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.93303","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}